Griseofulvin (Fulvicin)

Griseofulvin, available under the brand name Fulvicin among others, is an oral antifungal medication that has been used for decades to treat dermatophytosis, commonly known as ringworm, in cats. Derived from Penicillium griseofulvum, this medication was one of the first effective oral treatments for fungal skin infections and remains a viable option for treating dermatophyte infections in feline patients. While newer antifungal medications have become available with potentially fewer side effects and shorter treatment durations, griseofulvin continues to be used in veterinary medicine due to its proven efficacy, familiarity among practitioners, and cost-effectiveness.

Griseofulvin works through a unique mechanism of action that distinguishes it from other antifungal medications. The drug interferes with fungal cell division by disrupting the spindle apparatus during mitosis, preventing the fungal cells from reproducing normally. Griseofulvin binds to newly formed keratin in the skin, hair, and nails, making these tissues resistant to fungal invasion as they grow and replace infected structures. This mechanism means that the drug does not kill existing fungal elements but rather prevents new infection of growing tissues, requiring treatment to continue until all infected material has been replaced with healthy, drug-containing keratin.

Griseofulvin is available in different particle size formulations, including microsize and ultramicrosize preparations, which differ in their absorption characteristics. The ultramicrosize formulations have improved bioavailability and allow for lower doses to achieve equivalent blood levels, though microsize preparations are also effective when dosed appropriately. The medication is typically administered orally once or twice daily with food, as fat enhances absorption of the drug. Treatment duration for dermatophytosis is typically extended, often requiring six weeks or longer, continuing until fungal cultures confirm eradication of the infection.

While griseofulvin has a long track record of use in veterinary medicine, it does carry some important safety considerations. The medication is teratogenic and absolutely contraindicated in pregnant cats. Bone marrow suppression, particularly in cats infected with feline immunodeficiency virus, is a serious potential adverse effect. Veterinary supervision is essential for appropriate use of griseofulvin, including proper diagnosis of dermatophytosis, selection of appropriate candidates for therapy, accurate dosing, and monitoring for adverse effects throughout the treatment course.

The primary and essentially exclusive indication for griseofulvin in cats is the treatment of dermatophytosis, the fungal skin infection commonly known as ringworm. Dermatophytosis in cats is most commonly caused by Microsporum canis, which accounts for the vast majority of feline ringworm cases, though infections with Microsporum gypseum and Trichophyton species also occur. Griseofulvin is highly effective against these dermatophyte fungi and has been a mainstay of ringworm treatment in cats for many years. The medication is particularly valuable when systemic treatment is necessary due to widespread infection, recurrent disease, or failure to respond to topical therapy alone.

Ringworm in cats presents with variable clinical signs including circular areas of hair loss, broken hairs, scaling, crusting, and sometimes itching, though many infected cats show minimal clinical signs despite harboring the organism. Some cats, particularly longhaired breeds, may be asymptomatic carriers capable of spreading the infection to other animals and humans without showing obvious lesions themselves. Griseofulvin therapy helps eliminate the infection from these carriers and reduces the risk of transmission. Multi-cat households, shelters, and catteries often require systemic treatment programs including griseofulvin to control ringworm outbreaks.

Griseofulvin is specifically active against dermatophyte fungi and is not effective against other types of fungal infections. The drug has no activity against yeasts such as Candida or Malassezia, nor against the fungi that cause systemic mycoses such as Cryptococcus, Blastomyces, or Histoplasma. Therefore, accurate diagnosis of dermatophytosis is essential before initiating griseofulvin therapy. Diagnostic methods include Wood's lamp examination (though only some Microsporum canis strains fluoresce), direct microscopic examination of hairs and scale, and fungal culture, which remains the gold standard for confirming dermatophyte infection.

Veterinarians may choose griseofulvin for treating dermatophytosis when systemic antifungal therapy is indicated and the cat is an appropriate candidate for this medication. The drug is generally not used in cats with feline immunodeficiency virus infection or bone marrow disorders due to the risk of exacerbating these conditions. Pregnant cats should never receive griseofulvin due to its teratogenic effects. For cats that are not candidates for griseofulvin, alternative systemic antifungals such as itraconazole or terbinafine may be used instead.

Combination therapy utilizing both systemic griseofulvin and topical antifungal treatments is commonly employed for treating dermatophytosis, particularly in multi-animal households or when rapid reduction of environmental contamination is desired. Topical therapy helps kill fungal spores on the coat surface and reduces the amount of infectious material shed into the environment, while systemic therapy addresses the infection within the hair follicles and skin. Environmental decontamination is also an essential component of successful ringworm management.

Dosing of griseofulvin for cats requires veterinary guidance to ensure appropriate selection of the correct formulation and accurate dose calculation based on body weight. The dose varies depending on whether a microsize or ultramicrosize preparation is being used, with ultramicrosize formulations requiring lower doses to achieve equivalent blood levels due to their improved absorption. The veterinarian will prescribe the appropriate dose and formulation for the individual patient, and these instructions should be followed precisely.

Griseofulvin is typically administered orally once or twice daily, depending on the specific dosing protocol prescribed by the veterinarian. The medication should always be given with food, preferably a meal containing some fat, as dietary fat significantly enhances absorption of griseofulvin. Giving the medication on an empty stomach results in reduced absorption and may compromise treatment effectiveness. If the cat will not eat a regular meal, giving the medication with a small amount of a high-fat treat such as a dab of butter or a commercial treat may help improve absorption.

Treatment duration for dermatophytosis with griseofulvin is typically extended, often requiring a minimum of six to eight weeks, and therapy should continue for at least two weeks beyond clinical resolution or until negative fungal cultures are obtained. Premature discontinuation of treatment is a common cause of treatment failure and recurrence of infection. Some cats, particularly those in multi-cat environments or with extensive infection, may require even longer treatment courses. The veterinarian will advise when treatment can be safely discontinued based on clinical assessment and fungal culture results.

Administering griseofulvin tablets to cats can be challenging, as with any oral medication in this species. The tablets can be given directly by mouth or may be hidden in a small amount of a palatable food. Crushing tablets and mixing with food may be acceptable for some preparations but should be confirmed with the veterinarian or pharmacist, as crushing may affect absorption characteristics of certain formulations. Liquid suspensions may be available and can facilitate more accurate dosing for smaller cats.

If a dose is missed, it should be given as soon as remembered. If it is close to the time for the next scheduled dose, the missed dose should be skipped and the regular schedule resumed. Doses should never be doubled to compensate for missed doses. If doses are frequently missed, the treatment duration may need to be extended to ensure adequate therapy. Pet owners having difficulty administering the medication should discuss alternative approaches or formulations with their veterinarian.

Regular follow-up appointments during griseofulvin therapy allow the veterinarian to assess treatment response, monitor for adverse effects, and determine when treatment can be discontinued. Fungal cultures, rather than clinical appearance alone, are the best guide for determining treatment duration, as cats may appear clinically cured while still harboring fungal organisms.

Griseofulvin can cause a range of side effects in cats, and awareness of these potential adverse effects is important for pet owners whose cats are receiving this medication. While many cats tolerate griseofulvin without significant problems, the medication has a narrower safety margin than some newer antifungal alternatives, and certain cats are at increased risk for serious complications. Close monitoring throughout the treatment course helps identify problems early when they can be most effectively managed.

Gastrointestinal side effects are among the most common adverse reactions to griseofulvin in cats. Decreased appetite, nausea, vomiting, and diarrhea may occur, particularly during the early stages of treatment. Administering the medication with food may help reduce gastrointestinal upset. If these effects are mild, they may resolve as the cat adjusts to the medication. However, persistent or severe gastrointestinal symptoms should be reported to the veterinarian, as dose adjustment or discontinuation of therapy may be necessary.

Bone marrow suppression is one of the most serious potential adverse effects of griseofulvin in cats. This condition results in decreased production of blood cells, which can lead to anemia (low red blood cells), neutropenia (low white blood cells), or thrombocytopenia (low platelets). Signs of bone marrow suppression may include lethargy, pale gums, fever, increased susceptibility to infections, or bleeding tendencies. Cats infected with feline immunodeficiency virus (FIV) are particularly susceptible to bone marrow toxicity and should not receive griseofulvin. Regular blood work monitoring may be recommended during extended treatment courses to detect early signs of bone marrow effects.

Neurological side effects have been reported in cats receiving griseofulvin, including ataxia (incoordination), depression, and behavioral changes. These effects appear to be more common at higher doses or in certain susceptible individuals. Any changes in behavior, gait, or neurological function during treatment should be promptly reported to the veterinarian.

Skin reactions, paradoxically including photosensitivity and other dermatological changes, may occasionally occur in cats receiving griseofulvin. Some cats may develop increased sensitivity to sunlight during treatment. Allergic reactions, while uncommon, can manifest as facial swelling, hives, or more severe systemic signs. Any evidence of an allergic reaction requires immediate veterinary attention, and the medication should be discontinued if significant hypersensitivity occurs.

Griseofulvin has several important contraindications that must be carefully considered before this medication is prescribed for a cat. The most absolute contraindication is pregnancy, as griseofulvin is a known teratogen that causes severe birth defects in multiple species including cats. Under no circumstances should griseofulvin be administered to pregnant cats, and cats receiving the medication should be prevented from becoming pregnant during treatment and for at least one month after the last dose. Breeding queens should complete treatment and wait an appropriate period before breeding.

Cats infected with feline immunodeficiency virus (FIV) should not receive griseofulvin due to their significantly increased risk of developing bone marrow suppression. FIV-positive cats have compromised immune systems and are more susceptible to the myelosuppressive effects of the drug, which can lead to life-threatening cytopenias. Alternative antifungal medications such as itraconazole or terbinafine should be used for treating dermatophytosis in FIV-positive cats. Testing for FIV status may be advisable before starting griseofulvin therapy, particularly in cats with unknown viral status.

Cats with pre-existing bone marrow disorders, anemia, or other blood cell abnormalities should not receive griseofulvin due to the risk of worsening these conditions. The medication can suppress bone marrow function even in healthy cats, and those with already compromised blood cell production are at particularly high risk. A complete blood count before starting therapy can help identify cats that may be unsuitable candidates for griseofulvin treatment.

Known hypersensitivity to griseofulvin is a contraindication to its use. Cats that have previously experienced allergic reactions or other serious adverse effects from griseofulvin should not be given this medication again. Cross-reactivity with penicillin may occur in some cases, as griseofulvin is derived from a Penicillium species, so cats with documented penicillin allergies may potentially react to griseofulvin, though this relationship is not well-established in cats.

Cats with severe liver disease may have impaired ability to metabolize griseofulvin, potentially leading to drug accumulation and increased toxicity. While mild liver enzyme elevations are not necessarily contraindications, significant hepatic dysfunction warrants careful consideration of whether griseofulvin is the most appropriate choice or whether alternative antifungals would be safer. Liver function assessment through blood work is advisable before initiating therapy.

Before starting griseofulvin therapy, pet owners should inform the veterinarian of all medications, supplements, and other treatments their cat is currently receiving. While drug interactions with griseofulvin are generally less extensive than with some other antifungal medications, important interactions do exist that can affect treatment safety and efficacy. A complete medication history allows the veterinarian to identify and manage potential interactions appropriately.

Griseofulvin may reduce the effectiveness of certain medications by enhancing their metabolism through liver enzymes. This interaction is of primary concern in human medicine with medications such as oral contraceptives and warfarin, but similar effects on the metabolism of other drugs could theoretically occur in cats. If a cat is receiving chronic medications for other conditions, the veterinarian should be aware of this when considering griseofulvin therapy.

Phenobarbital and other enzyme-inducing drugs may reduce griseofulvin blood levels by increasing its metabolism, potentially compromising treatment effectiveness. Cats receiving anticonvulsant therapy may require higher doses of griseofulvin to achieve therapeutic effect, or alternative antifungal medications may be more appropriate. The veterinarian will consider these interactions when selecting antifungal therapy for cats on chronic medications.

Concurrent use of griseofulvin with other medications that can affect the bone marrow should be avoided or carefully monitored due to the potential for additive myelosuppressive effects. This includes certain antibiotics, chemotherapy agents, and other drugs known to cause bone marrow suppression. Enhanced monitoring through regular blood counts is advisable if concurrent use cannot be avoided.

The absorption of griseofulvin is significantly enhanced by dietary fat, which is considered a beneficial interaction that is exploited therapeutically by recommending administration with fatty food. However, medications or supplements that alter fat absorption could potentially affect griseofulvin bioavailability. The timing of other oral medications relative to griseofulvin administration should be coordinated to ensure optimal absorption of all agents.

Pet owners should not add any new medications, supplements, or over-the-counter products to their cat's regimen without first consulting with the veterinarian. Even seemingly harmless supplements or flea and tick products should be discussed to ensure they will not interact adversely with griseofulvin therapy.

Several important precautions and warnings apply to the use of griseofulvin in cats, and understanding these helps ensure the safest possible treatment. The most critical warning concerns use in pregnant cats, as griseofulvin causes severe birth defects and should never be administered to pregnant animals. Cats of breeding age should be confirmed not pregnant before starting therapy, and appropriate measures to prevent pregnancy should be taken during treatment and for at least one month following discontinuation of the drug.

Regular monitoring through blood work is advisable during extended griseofulvin therapy to detect bone marrow suppression before it becomes clinically severe. A complete blood count before starting treatment establishes baseline values, and periodic rechecks during treatment allow early detection of decreasing blood cell counts. The frequency of monitoring depends on the treatment duration, individual patient factors, and the veterinarian's clinical judgment. Cats showing signs of lethargy, pale gums, fever, or bleeding should have blood work performed promptly.

Accurate weighing of the cat is essential for correct dose calculation, as griseofulvin has a relatively narrow margin between therapeutic and toxic doses. Kittens and small cats require careful dose calculation to avoid overdosing. Weight changes during treatment should be reported to the veterinarian so doses can be adjusted if necessary. Using a reliable scale and weighing the cat regularly throughout the treatment course helps ensure appropriate dosing.

Certain breeds and individual cats may be more susceptible to griseofulvin toxicity, though specific breed-related sensitivities have not been well-characterized in the veterinary literature. Any cat that has previously experienced adverse effects from griseofulvin should be treated with an alternative antifungal if ringworm treatment is needed again. Cats with chronic health conditions, particularly those affecting the liver or bone marrow, require careful evaluation before griseofulvin is prescribed.

Environmental precautions are important when treating ringworm, as the fungal spores are highly persistent and can contaminate the household environment. Treatment of the cat alone without environmental decontamination may result in reinfection. The veterinarian can provide guidance on appropriate cleaning protocols, which typically include frequent vacuuming, disinfection of hard surfaces, and laundering of bedding and other fabric items that the cat contacts.

Human health considerations are relevant when treating feline dermatophytosis, as ringworm is zoonotic and can be transmitted to people. Family members, particularly children, elderly individuals, and immunocompromised persons, should minimize direct contact with infected cats until the infection is controlled. Handwashing after handling the cat and wearing gloves when applying topical treatments help reduce transmission risk. Human family members who develop suspicious skin lesions should consult their physician.

Griseofulvin tablets should be stored at controlled room temperature, typically between 15 and 30 degrees Celsius (59 to 86 degrees Fahrenheit), in a dry location protected from excessive heat and direct sunlight. The medication should be kept in its original container with the cap tightly closed to protect it from moisture and light, both of which can degrade the drug over time. Avoiding storage in humid environments such as bathrooms helps maintain the medication's stability and effectiveness.

If a liquid suspension formulation of griseofulvin is prescribed, it may have specific storage requirements that differ from tablets. The suspension should be stored according to the instructions provided by the pharmacist, which may include refrigeration for certain preparations. Before each dose, the suspension should be shaken well to ensure uniform distribution of the medication throughout the liquid. The suspension should be inspected visually before administration, and any product that has changed color, developed particles, or appears abnormal should not be used.

Expiration dates should be checked regularly, and any medication that has passed its expiration date should be properly disposed of and replaced with fresh product. Using expired medication may result in reduced effectiveness, potentially prolonging the cat's infection and increasing the risk of environmental contamination and spread to other animals or people. The veterinarian or pharmacy can provide a fresh supply of medication if the original prescription has expired before treatment is complete.

Griseofulvin should be stored securely out of reach of children and other pets. While the medication requires a prescription and is intended only for the patient it was dispensed for, accidental ingestion by other household members could occur if medications are not properly secured. A locked cabinet or other secure storage location prevents accidental access. Given the teratogenic nature of griseofulvin, women who are or might become pregnant should avoid handling broken tablets or spilled medication.

Proper disposal of unused or expired griseofulvin should be done according to local guidelines for pharmaceutical waste. Many pharmacies and veterinary clinics participate in medication take-back programs that ensure safe disposal. If such programs are not available locally, the medication can be mixed with an undesirable substance such as used coffee grounds, placed in a sealed container, and disposed of with regular household trash. Flushing medications is generally not recommended due to environmental concerns.

Griseofulvin can generally be used in cats of all breeds, though certain breed-related factors may influence susceptibility to ringworm infection, treatment decisions, and monitoring requirements. Understanding these considerations helps ensure appropriate use of the medication across different feline populations.

Persian, Himalayan, and other longhaired cat breeds have been noted to have higher rates of dermatophytosis and may be more likely to be asymptomatic carriers of dermatophyte fungi. The dense, long coats of these breeds may provide a favorable environment for fungal growth and make it more difficult to detect early lesions. Treatment of ringworm in longhaired cats often benefits from clipping of the coat to improve penetration of topical treatments and reduce environmental contamination. Extended griseofulvin treatment courses may be necessary for these breeds to ensure complete eradication of infection.

Certain purebred cats may be maintained in breeding programs or catteries where ringworm can become endemic. In these situations, systematic treatment and testing protocols are essential for controlling the infection. However, the teratogenic nature of griseofulvin poses particular challenges in breeding situations, as the medication cannot be used in pregnant queens and breeding must be delayed until treatment is completed and an appropriate waiting period has passed.

Size variations among cat breeds affect griseofulvin dosing, with larger cats requiring appropriately higher doses based on body weight and smaller cats needing proportionally smaller amounts. Accurate weighing is essential for all cats but is particularly important for very small individuals where minor dosing errors represent a larger percentage of the total dose. Ultramicrosize formulations, which allow lower total doses, may be advantageous for very small cats.

Age considerations apply across all breeds. Kittens are frequently affected by ringworm and are often the source of infection in multi-cat households. However, young kittens may be more susceptible to adverse effects from griseofulvin, and some veterinarians prefer to use alternative antifungals in very young cats. Geriatric cats may have reduced liver or kidney function that affects drug metabolism and elimination. The veterinarian will consider individual patient factors including breed, age, and overall health status when prescribing griseofulvin and determining appropriate monitoring protocols.

Several other antifungal medications can be used to treat dermatophytosis in cats and may be preferred over griseofulvin in certain situations. Itraconazole is a triazole antifungal that has become a common first-line choice for treating ringworm in cats, offering good efficacy with a safety profile that may be more favorable than griseofulvin for some patients. Itraconazole can be used in FIV-positive cats and does not carry the same teratogenic concerns as griseofulvin, though it is not recommended during pregnancy without careful risk-benefit assessment. Treatment courses with itraconazole may be shorter than those required with griseofulvin.

Terbinafine is an allylamine antifungal that concentrates in keratinized tissues and has excellent activity against dermatophyte fungi. This medication has become increasingly popular for treating feline ringworm due to its efficacy and the potential for shorter treatment durations compared to older antifungals. Terbinafine may be particularly useful in cases that have not responded adequately to other treatments. The medication is generally well-tolerated in cats, though gastrointestinal side effects and hepatotoxicity can occur.

Fluconazole is a triazole antifungal that may be used for dermatophytosis, though it may not be as effective against dermatophytes as some other agents. Fluconazole offers the advantage of once-daily dosing and excellent bioavailability. It may be useful in specific situations or when other antifungals are contraindicated, but is more commonly reserved for other fungal infections such as cryptococcosis.

Topical antifungal treatments play an important role in treating dermatophytosis and are often used in conjunction with systemic medications like griseofulvin. Topical options include miconazole, clotrimazole, and antifungal shampoos containing various active ingredients. Lime sulfur dip is an effective topical treatment that can be used as part of a comprehensive ringworm management program. Topical therapy helps reduce environmental contamination by killing fungal spores on the coat surface.

The choice among available antifungal medications should be made by a veterinarian based on the individual patient's health status, the extent of infection, potential contraindications, and practical considerations such as ease of administration and cost. Substituting one antifungal for another without professional guidance is not advisable, as different medications have different spectrums of activity, dosing requirements, and safety considerations.